Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2024 08:00 ET | Source: Humacyte, Inc

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

– sdATEVs maintained sustained patency throughout the six-month study – – sdATEV was observed to recellularize with host cells and remodel to effectively reduce the initial size mismatch between the...
November 14, 2024 08:00 ET | Source: Humacyte, Inc

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
November 08, 2024 08:00 ET | Source: Humacyte, Inc

Humacyte Third Quarter 2024 Financial Results and Business Update

- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV)...
November 06, 2024 08:00 ET | Source: Humacyte, Inc

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

DURHAM, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
October 28, 2024 07:00 ET | Source: Humacyte, Inc

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

– ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access – - ATEV also showed superior...
October 23, 2024 08:00 ET | Source: Humacyte, Inc

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

DURHAM, N.C., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
October 08, 2024 08:00 ET | Source: Humacyte, Inc

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
October 04, 2024 08:00 ET | Source: Humacyte, Inc

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

DURHAM, N.C., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
September 26, 2024 17:26 ET | Source: Humacyte, Inc

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
September 19, 2024 08:00 ET | Source: Humacyte, Inc

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

- New U.S. patent covers the design and composition of the BVP - - Positive results from ongoing preclinical studies support the potential of the BVP to deliver insulin-producing islets as a...